A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants

Launched by ABBVIE · Jul 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a medicine called ABBV-932 behaves in the body when taken together with another medicine called Itraconazole. The main goal is to see if there are any side effects and to understand how ABBV-932 moves through the body in healthy adults. This is an early-phase study, which means it is mainly focused on safety and how the body processes the medicine, rather than treating any illness.

To take part, participants need to be healthy adults with a body weight and height that result in a Body Mass Index (BMI) between 18.0 and 32.0. They should have no serious health problems like heart, lung, liver, or mental health conditions, and no recent history of suicidal thoughts or behavior. Before joining, participants will have a medical check-up including tests like a heart rhythm check (called an ECG). The study is not yet recruiting, and it is open to adults of any gender within the specified age range. If you join, you can expect close monitoring for any side effects and tests to track how the medicine is absorbed and processed in your body.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
• • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG
• Exclusion Criteria:
• • History: of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
• • History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia - Suicide Severity Rating Scale (C-SSRS).